MedicarePartD.guide

A non-government resource built from CMS public data

CDK4/6 inhibitors for breast cancer on AARP Medicare Rx Preferred from UHC (S5820-038)

Ibrance, Kisqali and Verzenio, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), U.S. Virgin Islands
Premium
$114.80/month
Deductible
$615.00
Change plan

3 of 3 CDK4/6 inhibitors are covered on this plan. All 3 require prior authorization.

  • Ibrance
    palbociclib
    Covered · prior auth
    from $5,052.43
    Tier 5
  • Kisqali
    ribociclib
    Covered · prior auth
    from $2,856.09
    Tier 5
  • Verzenio
    abemaciclib
    Covered · prior auth
    $4,853.22
    Tier 5

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list